Pediatric and Congenital Vascular Surgery

68.1Pediatric and congenital vascular disease frame

The first decision is not whether the child needs an operation; it is what disease family the vascular finding belongs to. A red infant lesion, a swollen limb, a narrow aortic isthmus, a renal-vein thrombus, a dilated aorta in a syndromic child, and a coronary aneurysm after Kawasaki disease may all arrive under a vascular label, but they do not share a treatment pathway. The safe opening move is to classify the mechanism, define the physiologic consequence, and ask which decision will still make sense after growth, reintervention, and adult care are considered.

For vascular anomalies, the clinical boundary is the ISSVA distinction between vascular tumors and vascular malformations. Tumors are proliferative lesions; malformations are developmental vascular abnormalities that enlarge through expansion rather than tumor proliferation. Malformations are then organized as simple, combined, involving major named vessels, or associated with other anomalies. That vocabulary changes the first referral and the first treatment: a proliferating infantile hemangioma may need early medical assessment, whereas a venous-lymphatic or major-vessel malformation needs lesion-specific imaging and anomaly-team planning rather than default excision. Clinical Practice Guideline 2019 · ISSVA Classification Vascular 2018

Named-vessel congenital disease demands the same discipline. Coarctation is not a diameter diagnosis. The decision to intervene is built from the hemodynamic gradient, upper-lower extremity blood-pressure behavior, collateral formation, arch hypoplasia, associated cardiac anatomy, age, and the durability of each repair option. The 2018 AHA/ACC congenital heart disease guideline uses a peak-to-peak catheterization gradient of at least 20 mmHg, or significant coarctation on cross-sectional imaging with collateral vessels, as a treatment boundary; pediatric modality selection still has to be narrowed by age and anatomy rather than borrowed as a generic adult catheter algorithm. ACC/AHA 2018 · Comparison surgical stent 2011

Pediatric thrombosis is also an anatomic-risk problem, not an adult venous-thromboembolism template. Neonatal or childhood renal vein thrombosis should be described by laterality, renal impairment, and inferior vena cava extension. Low-risk unilateral disease may be observed with supportive care or anticoagulated in selected cases, whereas bilateral disease with renal impairment or extension into the inferior vena cava moves the discussion toward anticoagulation and, in selected severe presentations, thrombolysis followed by anticoagulation. ASH 2024 · DVT 2012

Aortopathy introduces a family decision boundary. A child or adolescent with thoracic aortic dilation, a syndromic phenotype, early dissection in the family, or a first-degree relative with aortic disease should be evaluated as a possible heritable aortopathy rather than as an isolated aneurysm. Contemporary aortic guidance and the pediatric aortopathy statement both frame care around genotype, phenotype, family history, size, growth, and cascade testing when a pathogenic familial variant is identified. AHA 2024 · ACC/AHA 2022

The vascular surgeon’s contribution is to keep these boundaries visible. A child with a high-risk infantile hemangioma, a major-vessel venous malformation, native coarctation, unilateral renal vein thrombosis, Marfan-spectrum aortopathy, or Kawasaki coronary aneurysm needs a different first consultation, different imaging questions, different perioperative planning, and different family counseling. The practical rule is therefore simple: name the mechanism before naming the procedure.

68.2Diagnostic workup, imaging, and growth-aware planning

The diagnostic workup should decide what must not be missed before it decides how the lesion might be treated. In children, measurements are body-size dependent, vascular access is finite, and a technically attractive catheter maneuver may be the wrong answer if the lesion will grow, the arch will remain hypoplastic, or a family aortopathy will change the surveillance threshold.

For vascular anomalies, the imaging request should follow the classification question. The clinician should first ask whether the finding is a vascular tumor or a malformation; for malformations, the report should define whether the lesion is simple or combined, whether it involves major named vessels, and whether it is associated with other anomalies. Pediatric vascular-malformation imaging guidance supports using imaging to define extent, flow behavior, tissue and organ involvement, and features that change treatment selection, rather than imaging an undifferentiated “birthmark.” Pediatric Vascular Malformations 2022 · ISSVA Classification Vascular 2018

Coarctation imaging should answer the questions that change repair choice. The report should identify the site and length of narrowing, arch hypoplasia, collateral vessels, associated cardiac or arch anatomy, and whether the anatomy is plausible for catheter therapy at the child’s age and size. A catheter peak-to-peak gradient of at least 20 mmHg, or significant narrowing on cross-sectional imaging with collateral formation, supports intervention, but the route of repair is still conditioned by age, arch anatomy, and center experience. ACC/AHA 2018 · Comparison surgical stent 2011

Kawasaki coronary disease shows why the same artery diameter can mean different things in different children. McCrindle 2017 The coronary report should state the z-score and the absolute diameter, because aneurysm categories and long-term thrombosis or stenosis risk are interpreted through both body-size normalization and absolute caliber. For a vascular operation outside the coronary circulation, the important point is not to list “Kawasaki disease” as remote history, but to identify the current coronary-risk category before anesthesia and antithrombotic planning.

Aortic workup should bring inheritance into the imaging plan. Pediatric aortopathy care is not driven by diameter alone; genotype, family history, syndromic features, segment involved, growth rate, blood pressure, and operative risk have to be integrated. Genetic testing is recommended when the phenotype or family history suggests heritable thoracic aortic disease, and identification of a pathogenic familial variant should trigger cascade testing in first-degree relatives. AHA 2024 · ACC/AHA 2022

The useful baseline note is therefore anatomical and longitudinal. It names the diagnosis, records body-size-aware measurements, states which vessels are involved, identifies collaterals or organ-threatening extension, documents access sites already used or to be preserved, and says why observation, medical therapy, catheter intervention, open repair, or referral to a specialist congenital or vascular-anomaly team is being chosen. That documentation is not administrative; it is the scaffold for the next imaging study and the next decade of decisions.

68.3Open, endovascular, and nonoperative treatment selection

Treatment selection in pediatric and congenital vascular disease is a durability decision. The question is not only whether a lesion can be crossed, dilated, embolized, stented, excised, or anticoagulated today. The more important question is whether that choice fits the diagnosis, the child’s size, expected growth, future access needs, and the probability that the same vascular bed will need surveillance or repeat treatment for decades.

Coarctation illustrates why modality cannot be generalized across ages. Intervention is supported when the catheter peak-to-peak gradient is at least 20 mmHg or when cross-sectional imaging shows significant coarctation with collateral formation, but the repair route is not interchangeable. Neonates and young children, especially those with complex arch hypoplasia, usually require surgical decision-making in a congenital program; balloon angioplasty or stenting is considered only when age, vessel size, arch anatomy, and institutional expertise make the catheter option durable rather than merely feasible. The CCISC observational comparison of surgical, stent, and balloon approaches supports framing native coarctation as an age- and anatomy-dependent choice rather than a single-lesion algorithm. ACC/AHA 2018 · Comparison surgical stent 2011

Renal vein thrombosis often makes nonoperative care the correct active treatment. A unilateral renal vein thrombosis without renal impairment or inferior vena cava extension may be followed with supportive monitoring or treated with a finite course of anticoagulation, depending on the child’s risk profile. Bilateral renal vein thrombosis, renal impairment, or extension into the inferior vena cava moves the balance toward anticoagulation, with thrombolysis reserved for selected high-risk presentations and followed by anticoagulation when used. This plan should be written as an anatomic and renal-risk statement, not as “pediatric DVT” by analogy to adult lower-extremity disease. ASH 2024 · DVT 2012

Infantile hemangioma is the vascular anomaly in which early medical therapy most clearly prevents the wrong operation. The AAP infantile hemangioma guideline emphasizes prompt recognition of high-risk lesions, and the propranolol randomized trial enrolled infants 1–5 months old with infantile hemangiomas requiring systemic treatment because of proliferation with functional complications, disfigurement, or risk of complication. That evidence supports propranolol for selected infantile hemangiomas; it does not justify treating every vascular birthmark, venous malformation, lymphatic malformation, or combined anomaly as a hemangioma. Clinical Practice Guideline 2019 · L aut Labr 2015

Sirolimus should be discussed with the same diagnostic restraint. The Adams study of complicated vascular anomalies stratified patients by ISSVA-defined lesion type and showed lesion-specific signals of benefit, but the population was heterogeneous and response should not be assumed across all malformations. In a surgical consultation, the practical use of sirolimus evidence is to ask whether the child’s exact anomaly type, extent, symptoms, and monitoring capacity match the studied population closely enough to support medical therapy or combined therapy. Efficacy Safety Sirolimus 2016 · ISSVA Classification Vascular 2018

For malformations involving major named vessels, treatment often requires staged rather than single-modality thinking. Imaging should define extent, flow behavior, tissue planes, venous or lymphatic involvement, organ threat, and access feasibility before the team chooses embolization, sclerotherapy, surgery, medical therapy, observation, or combinations. The decision boundary is not “open versus endovascular”; it is whether the intervention treats the correct lesion while preserving growth, function, and future access. Pediatric Vascular Malformations 2022 · ISSVA Classification Vascular 2018

Families should hear the same logic in plain terms. A neonate with arch hypoplasia is not the same candidate as an older child with focal coarctation anatomy. A unilateral renal vein thrombosis without renal impairment is not the same risk state as bilateral disease with renal dysfunction. A high-risk proliferating infantile hemangioma is not the same lesion as a venous-lymphatic malformation. Consent is stronger when these distinctions are made before the treatment is chosen.

68.4Access, anesthesia, anticoagulation, and complication prevention

The procedural plan should protect the child from both immediate complications and future loss of options. Small arteries, small veins, low physiologic reserve, growth, and decades of possible reintervention make access, anesthesia, anticoagulation, and surveillance inseparable parts of the same decision. A femoral artery, iliac vein, or arch segment used today may become the limiting variable in the next procedure.

For coarctation, access and anesthesia planning follow from the lesion’s hemodynamic and anatomic severity. A gradient of at least 20 mmHg or significant coarctation with collaterals supports intervention, but the procedural risk profile depends on arch hypoplasia, collateral burden, associated cardiac anatomy, age, and the planned route. In a neonate or small child, the question is often how to achieve durable arch repair without creating access injury or residual obstruction; in an older child or adolescent, catheter therapy may be reasonable only when vessel caliber, landing zones, and operator experience make it safe. ACC/AHA 2018 · Comparison surgical stent 2011

Vascular-anomaly procedures should begin with the anomaly category in the operative plan. A localized vascular tumor, a venous malformation, a lymphatic malformation, and a combined malformation involving major named vessels carry different bleeding, lymphatic, wound-healing, and access risks. Pediatric imaging recommendations support defining extent and vessel involvement before intervention, because the complication to prevent may be hemorrhage, lymphatic leak, thrombosis, functional loss, or simply an incomplete procedure that makes later treatment harder. Pediatric Vascular Malformations 2022 · ISSVA Classification Vascular 2018

Inherited aortopathy changes what counts as a routine vascular procedure. A child with suspected Marfan, Loeys-Dietz, vascular Ehlers-Danlos, ACTA2-related disease, or another heritable aortic condition may have fragility, multisite disease, relatives at risk, and lower tolerance for poorly defined follow-up. Genetic testing and cascade testing recommendations should therefore be connected to the operative plan when the phenotype or family history suggests heritable thoracic aortic disease. AHA 2024 · ACC/AHA 2022

Blood-pressure control is also a complication-prevention tool. Ambulatory blood-pressure monitoring helps distinguish white-coat from masked hypertension and is recommended after coarctation repair; this matters before and after procedures because persistent or masked hypertension can affect aortic, arch, renal, and anesthesia risk. Clinical Practice Guideline 2017 The follow-up plan should specify how blood pressure will be measured, not merely that it should be “watched.”

Kawasaki coronary aneurysms should be risk-stratified before noncoronary vascular procedures. The AHA Kawasaki statement frames coronary aneurysm severity by z-score and absolute diameter, with the largest aneurysm categories carrying the greatest long-term risk of thrombosis, stenosis, and myocardial infarction. McCrindle 2017 A vascular procedure in such a child may need cardiology input, anesthesia planning around coronary risk, and explicit coordination of antiplatelet or anticoagulant therapy.

The pre-procedure note should therefore state the diagnosis, anatomy, growth constraint, access plan, preserved access sites, anticoagulation rationale, blood-pressure plan, and aortopathy or coronary risk when present. Technical success is incomplete in a child if the procedure solves today’s lesion while creating undocumented barriers for the next team.

68.5Transition, surveillance, family counseling, and evidence limits

Pediatric vascular care ends poorly when the child leaves with a procedure name instead of a vascular story. The transition plan should tell future clinicians what the diagnosis is, what anatomy was treated or left alone, what risks remain because of growth, which relatives may need evaluation, and which medications or surveillance tests are tied to a specific lesion rather than to habit.

After coarctation repair, patency is only one surveillance question. The care plan should include the original anatomy, repair method, residual arch findings, collateral history, access sites used, and blood-pressure behavior. Ambulatory blood-pressure monitoring is recommended after coarctation repair and is useful because masked hypertension may persist despite acceptable clinic readings. Adult congenital or vascular follow-up should therefore receive both the anatomic record and the blood-pressure record. ACC/AHA 2018 · Clinical Practice Guideline 2017 · Comparison surgical stent 2011

Heritable aortic disease requires family counseling at the first durable diagnosis, not years later. When the phenotype or family history suggests heritable thoracic aortic disease, genetic testing is recommended; when a pathogenic familial variant is identified, first-degree relatives should be offered cascade testing. The child’s surveillance interval and repair threshold should be interpreted through genotype, phenotype, family history, size, growth, and comorbidity, rather than through an isolated diameter copied from adult aneurysm care. AHA 2024 · ACC/AHA 2022

Vascular-anomaly counseling should separate the diagnosis from the treatment promise. ISSVA terminology gives families and clinicians a shared map—vascular tumor versus malformation, simple versus combined, major named-vessel involvement, and association with other anomalies—but it does not remove all uncertainty. Pediatric vascular-malformation imaging and classification may evolve as the lesion grows or as molecular information becomes available, so follow-up should state which features are known, which are provisional, and what findings should trigger reassessment. Pediatric Vascular Malformations 2022 · ISSVA Classification Vascular 2018

For infantile hemangioma, the evidence boundary is the studied population. The AAP guideline and propranolol trial evidence support early recognition and systemic treatment for selected high-risk infantile hemangiomas, particularly proliferating lesions with functional risk, disfigurement risk, or complication risk. Families should not hear that propranolol treats all vascular birthmarks, and clinicians should not use propranolol response as a substitute for diagnosing malformations that need different imaging and care. Clinical Practice Guideline 2019 · L aut Labr 2015

For sirolimus, the evidence boundary is lesion type and monitoring burden. The Adams trial supports considering sirolimus in selected complicated vascular anomalies, but responses were not uniform across ISSVA-defined categories and small lesion-specific strata limit broad extrapolation. Counseling should name the anomaly type, the goal of therapy, expected monitoring, infection and medication-safety issues, and the possibility that a complex malformation may need combined medical, interventional, and surgical care. Efficacy Safety Sirolimus 2016 · ISSVA Classification Vascular 2018

Kawasaki coronary disease and pediatric renal vein thrombosis also need explicit downstream language. A Kawasaki history should be translated into current coronary z-score and absolute-diameter risk category, because coronary aneurysm severity affects thrombosis, stenosis, myocardial-infarction risk, and perioperative planning. A renal vein thrombosis history should state laterality, renal function, caval extension, treatment course, and the reason anticoagulation was used, withheld, or stopped. ASH 2024 · McCrindle 2017 · DVT 2012

A strong transfer letter reads like a map for the next vascular decision. It should name the disease in specific terminology, list the anatomy and body-size-aware measurements that matter, document prior access and repairs, state antithrombotic rationale when relevant, identify blood-pressure and imaging surveillance needs, record genetic testing or family-testing recommendations, and specify which specialist team owns each risk. This is cautious synthesis from pediatric aortopathy and pediatric VTE principles rather than a promise that one template fits every child. AHA 2024 · ASH 2024